A new form of CAR T-cell therapy has been designed to find and destroy the cancer-driving stem cells responsible for a group ...

A study led by a researcher based at King's College London and McMaster University in Canada reveals how CAR-T cell therapy, a treatment that engineers a patient's own immune cells to recognize and ...

Researchers with the Charbonneau Cancer Institute at the University of Calgary and McMaster University have identified a unique target present on a specific group of solid cancerous tumors.

CAR T-cell therapy is expected to expand quickly across autoimmune skin diseases following an anticipated regulatory approval that might come as soon as this year.

Summary: Chimeric Antigen Receptor T-cell (CAR-T) therapy has revolutionized the treatment of liquid blood cancers by engineering a patient’s own immune cells to destroy malignant targets, replicating ...

Leading CAR T cell therapy researchers have developed a human-in-the-loop artificial intelligence (AI) framework that centers ...

After a median follow-up of 10 years, more than one-third of patients with large B-cell lymphoma and nearly half of patients ...

CAR-T therapy is a highly specialized treatment that requires careful patient selection and close monitoring. Some patients ...

CAR T-cell therapy is a personalized treatment that uses a patient’s own immune cells to fight cancer, making it effective but unsuitable for mass production, which increases the cost. The complex ...

Target selection leverages DLL3’s high tumor-surface expression in SCLC/LCNEC and limited normal-tissue expression, while dnTGFBR2 “armoring” aims to blunt TGF-β–mediated T-cell suppression. Dose ...

Doctors at the University of Washington and Fred Hutch Cancer Center have better characterized an emerging complication of chimeric antigen receptor (CAR) T-cell therapy. A recent paper in Movement ...